Zentalis Pharmaceuticals (ZNTL) said late Tuesday it will reduce its workforce by about 40% to focus on advancing the late-stage development of its experimental cancer therapy, azenosertib.
The company said the restructuring will extend its cash runway beyond the anticipated data readout from a potentially registration-enabling azenosertib study, expected by the end of 2026.
The workforce reduction is set to be substantially completed in Q2.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.